Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07633158 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)

Study acronym: PETRICHOR
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 11 → 15 locations Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 10 of 21 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 10 of 21 entries
  2. Trial sites expanded: 8 → 11 locationsv3
  3. Recruitment opened Trial sites expanded: 0 → 8 locations · Start date changed from estimate of Jun 30, 2026 to Jun 10, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Jun 30, 2026 to Jun 10, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose disease is inadequately controlled with systemic corticosteroids (SCS) and/or surgery. Eligible participants are newly initiated on subcutaneous tezepelumab in routine clinical practice, in accordance with the European Summary of Product Characteristics (SmPC). Treatment decisions are made jointly by patients and their physicians, independent of study enrollment. No additional diagnostic or monitoring procedures are applied; data are collected using epidemiological methods at baseline and during routine clinical visits for up to 104 weeks.
Trial Details
NCT Number NCT07633158
Lead Sponsor AstraZeneca
Conditions Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov